Article
Effects of the ABCG2 C421A Polymorphism on Plasma Gefitinib Concentration
2019-07-05
Abstract excerpt
<h4>Background: </h4> In patients with epidermal growth factor (EGFR) exon 21 L858R mutation-positive non-small cell lung cancer (NSCLC) treated with gefitinib, we found that a lower plasma gefitinib concentration was associated with shorter progression-free survival (PFS). ATP-binding castle protein G2 (ABCG2) is considered to inhibit the activities of certain gefitinib transporters, which affects drug pharmacoki...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 4ac84ff3-219e-56ba-a774-aac7f8ed9b90
- DOI
- 10.21203/rs.2.10916/v1
